Showing 3131-3140 of 5773 results for "".
- Pantheon Vision Secures a Second Tranche of Funding to Advance Bioengineered Corneal Implantshttps://modernod.com/news/pantheon-vision-secures-a-second-tranche-of-funding-to-advance-bioengineered-corneal-implants/2482197/Pantheon Vision, a pre-clinical stage medical device company developing bioengineered corneal implants, announced the closing of $1.8 million in a second tranche from KeraLink International (KLI). This comes following a previous $2.5 million investment from KLI last year, bringing the total
- SpyGlass Pharma Unveils 1-Year Data of Its Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucomahttps://modernod.com/news/spyglass-pharma-unveils-1-year-data-of-its-drug-delivery-platform-implanted-during-routine-cataract-surgery-in-eyes-with-glaucoma/2482196/SpyGlass Pharma announced 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ IOL-based drug delivery platform with bimatoprost at the time of cataract surgery. These data will be highlighted in a poster presentation
- Qlaris Bio’s Novel IOP-Lowering Product, QLS‑111, is Dosed in Phase 2 Trialshttps://modernod.com/news/qlaris-bios-novel-iop-lowering-product-qls111-is-dosed-in-phase-2-trials/2482195/Qlaris Bio announced the initiation and dosing of two separate US phase 2 masked, randomized clinical trials investigating QLS‑111 in patients with ocular hypertension and glaucoma. “The start of these phase 2 trials represents a key milestone in our goal of bringing QLS‑111
- Staar Surgical Celebrates Milestone and Unveils New EVO ICL Data at ASCRShttps://modernod.com/news/staar-surgical-celebrates-milestone-and-unveils-new-evo-icl-data-at-ascrs/2482194/At the ASCRS annual meeting in Boston, April 5-8, 2024, Staar Surgical will be celebrating a commercial milestone: 3 million lenses sold. Staar will be showcasing the clinical, practice and innovation advantages of the EVO ICL through a series of posters, presentations and educational p
- Aldeyra Plans to Resubmit New Drug Application for Reproxalap in Dry Eye Diseasehttps://modernod.com/news/aldeyra-plans-to-resubmit-new-drug-application-for-reproxalap-in-dry-eye-disease/2482193/About 4 months after receiving a complete response letter (CRL) from the FDA, Aldeyra Therapeutics announced a clinical development plan intended to enable resubmission of a new drug application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry
- Registration Now Open for Neuro-Optometric Rehabilitation Association 2024 Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-association-2024-conference/2482187/Registration is now open for the Neuro-Optometric Rehabilitation Association, International (NORA) 34th annual conference, September 19-22, at the Embassy Suites by Hilton Orlando, Lake Buena Vista South in Kissimmee, Florida. The NORA annual conference is a premier event for eye care a
- Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseaseshttps://modernod.com/news/azura-ophthalmics-to-present-new-data-supporting-the-potential-of-azr-md-001-to-be-the-first-ophthalmic-keratolytic-for-ocular-surface-diseases/2482185/Azura Ophthalmics announced multiple presentations highlighting positive efficacy and safety data from phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in meibomian gland dysfunction (MGD). This includes new, long-term data at ASCRS of the company’s lead drug candidat
- OnPoint Vision Initiates Phase 1 Trial of AccuraSee Intraocular Pseudophakic Capsular Lens Magnifierhttps://modernod.com/news/onpoint-vision-initiates-phase-1-trial-of-accurasee-intraocular-pseudophakic-capsular-lens-magnifier/2482184/OnPoint Vision announced open enrollment of the phase 1 IDE clinical trial of the AccuraSee Intraocular Pseudophakic Capsular Lens (IOPCL) Magnifier (MAG) for secondary implantation in the capsular bag with a pre-existing 6mm acrylic posterior chamber IOL. The IOPCL MAG is neu
- Iveric Bio Receives Permanent J-code for GA Treatment Izervayhttps://modernod.com/news/iveric-bio-receives-permanent-j-code-for-ga-treatment-izervay/2482181/Iveric Bio, a subsidiary of Astellas, announced that CMS has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPS) J-code for Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macula
- Opus Genetics Completes Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5https://modernod.com/news/opus-genetics-completes-dosing-in-first-cohort-of-phase-12-trial-of-gene-therapy-opgx-lca5-in-patients-with-lca5/2482180/Opus Genetics announced that the first cohort has completed dosing in its open-label, dose-escalation phase 1/2 clinical trial evaluating the subretinal delivery of OPGx-LCA5, an adeno-associated virus 8 (AAV8) vector designed to precisely deliver a functional LCA5 gene to the oute